Research Article

Upregulation of Plasminogen Activator Inhibitor-1 in Irradiated Recipient Arteries and Veins from Free Tissue Transfer Reconstruction in Cancer Patients

Bjorn O. Eriksson ^{1,2}, Caroline Gahm,^{1,2} and Martin Halle^{3,4}

¹Department of Otorhinolaryngology/Head and Neck Surgery, Karolinska University Hospital, 171 76 Stockholm, Sweden

²CLINTEC, Karolinska Institute, 171 77 Stockholm, Sweden

³Reconstructive Plastic Surgery, Karolinska University Hospital, 171 76 Stockholm, Sweden

⁴Department of Molecular Medicine and Surgery, Karolinska Institute, 171 77 Stockholm, Sweden

Correspondence should be addressed to Bjorn O. Eriksson; bjorn.eriksson@ki.se

Received 6 April 2018; Accepted 30 July 2018; Published 4 October 2018

Academic Editor: Stefan C. Vesa

Copyright © 2018 Bjorn O. Eriksson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Clinical studies have shown that radiotherapy can induce vascular disease at the site of exposure but is usually not clinically evident until years after treatment. We have studied irradiated human arteries and veins to better understand the underlying biology in search of future treatments. The aim was to investigate whether radiotherapy contributed to a sustained expression of plasminogen activator inhibitor-1 (PAI-1) in human arteries and veins. **Methods.** Irradiated arteries and veins were harvested, together with unirradiated control vessels, from patients undergoing free tissue transfer reconstruction at a median time of 90 weeks [5–650] following radiation exposure. Differential gene expression of PAI-1 was analysed, together with immunohistochemistry (IHC) and immunofluorescence (IF). **Results.** PAI-1 gene expression was increased in both arteries ($p = 0.012$) and veins ($p < 0.001$) in irradiated compared to unirradiated control vessels. IHC and IF indicated that cells expressing PAI-1 were located in the adventitia of both arteries and veins and colocalized with cells positive for CD68, CD45, and α -SMA in arteries and with CD45 and α -SMA in veins. **Conclusion.** The current study shows a sustained upregulation of PAI-1 in both arteries and veins after exposure to ionizing radiation, indicating a chronic inflammation mainly in the adventitia. We believe that the results contribute to further understanding of radiation-induced vascular disease, where targeting PAI-1 may be a potential treatment.

1. Introduction

Radiotherapy, a cornerstone in the treatment of patients with cancer, inevitably involves exposing healthy, surrounding tissue to ionizing radiation. Better overall treatment has led to an increasing number of cancer survivors and consequently more patients suffering from late adverse effects. Recent epidemiological studies have shown that localized cardiovascular disease may occur at the site of exposure, e.g., myocardial infarction or stroke after thorax or neck irradiation, respectively [1–6]. One theory of mechanisms of late vascular morbidity after radiotherapy is that oxidative stress leads to sustained inflammation of blood vessel walls, which

is suspected to contribute to the development of atherosclerosis and subsequent thromboembolic events [5, 7, 8]. Previous studies have shown an activation of the nuclear factor kappa-light-chain-enhancer of activated B-cells (NF- κ B) inflammatory pathway in irradiated arteries [9] and sustained expression of plasminogen activator inhibitor-1 (PAI-1), a downstream mediator in the NF- κ B cascade, in irradiated veins [10]. This may be of relevance for an increased risk of vascular occlusions observed in free-flap reconstructions after radiotherapy [11]. Surgery in previously irradiated patients can furthermore lead to a higher incidence of early and late posttherapeutic complications [12, 13], possibly related to detrimental effects of

TABLE 1: Demography of the cohorts. Seven patients participated in both the arterial and the venous groups (AV), 5 only in the arterial group (A), and 5 only in the venous group (V). (XRT = radiotherapy; Gy = gray; RFF = radial forearm flap; FIB = fibular flap; ALT = anterior lateral thigh; and DIEP = deep inferior epigastric perforator). Individual patient characteristics are listed in Supplementary Materials (available here).

Variable	Arterial group	Venous group	Total
Number (N)	12 (7 + 5)	12 (7 + 5)	17 (7 + 5 + 5)
Male (AV + A or V)	8 (6 + 2)	9 (6 + 3)	11 (6 + 2 + 3)
Female (AV + A or V)	4 (1 + 3)	3 (1 + 2)	6 (1 + 3 + 2)
Median age (years) [range]	63 [30–77]	59 [30–77]	59 [30–77]
RFF	5	6	7
FIB	6	4	7
ALT	1	1	2
DIEP	0	1	1
Median XRT dose (Gy) [range]	64 [60.3–68]	64 [50–68]	64 [50–68]
Median after XRT (weeks) [range]	118 [5–650]	69 [5–450]	90 [5–650]
Mean after XRT (weeks) [range]	161 [5–650]	117 [5–450]	150 [5–650]
Current smoking (n) [%]	2 [17]	2 [17]	3 [18]
Cardiovascular disease (n) [%]	1 [8]	2 [17]	2 [12]
Hypertension	4 [33]	3 [25]	4 [24]

radiotherapy on the endothelium [14, 15]. PAI-1 has been linked to thrombus formation in the microcirculatory bed [16], which might be a mechanism contributing to general surgical complications as well as flap bed-related complications in the reconstructive setting [10].

The aim of the current study was to corroborate previous evidence of an elevated expression of PAI-1 in previously irradiated arteries and veins by the analysis of the more endothelium-specific Serpine1, instead of Serpine2. By including both arteries and veins in the same analysis, we aimed to gain insight into differences between the respective vessel types and furthermore describe the morphology of PAI-1 expression within the vessel wall, which, to our knowledge, has never previously been described in humans.

2. Materials and Methods

2.1. Human Tissue Specimens. Seventeen pairs of arterial (group 1) and venous biopsies (group 2) were collected during reconstructive surgery with microvascular free tissue transfer in patients who had received prior radiotherapy due to cancer (see Table 1 for demographics and flap types). For 7 patients, there was enough material for all analyses (arterial and venous, AV), whereas for 5 patients the arteries (A) or the veins (V) were analysed, hence creating two groups of 12 patients (AV + A = group 1 and AV + V = group 2). The irradiated arteries of the head and neck were branches of the external carotid artery, and the veins were branches to the internal jugular vein whereas the donor site arteries and veins were correspondingly sized vessels (e.g., radial artery and vein and peroneal artery and vein). This setup ensured that each individual acted as their own control, and a discerning factor between blood vessels from the two sites was exposure to radiotherapy. The blood vessels were carefully freed from connective tissue under an operating microscope in order not to injure the endothelium. After excision, biopsies for gene expression analysis were

placed in RNAlater RNA Stabilization Reagent (Qiagen GmbH, Hilden, Germany), frozen and stored at -80°C until RNA extraction. Biopsies for immunohistochemistry (IHC) and immunofluorescence (IF) were fixed in 10% formalin and embedded in paraffin.

2.2. Demography. No major differences were observed in the comparison of background demographic data between the groups (Table 1). There was a male to female preponderance (11:6), and the median age was 59 years [30–77]. Median radiation dose was 64 Gy [50–68], and median time since last radiotherapy session was 90 weeks [5–650], with a mean of 150 weeks. Seventeen percent of the patients were current smokers, 12% had a history of cardiovascular disease (peripheral vascular disease, myocardial infarction, cerebral infarction), and the prevalence of hypertension was 24%. All participants signed informed consent sheets. The study was approved by the Ethical Committee of Stockholm and was performed in agreement with institutional guidelines and the principles of the Declaration of Helsinki.

2.3. qPCR Analysis. Ribonucleic acid (RNA) extraction was performed using the RNeasy Mini kit (Qiagen GmbH, Hilden, Germany), with an on-column DNase digestion step. RNA quality was analysed via microcapillary electrophoresis via an Agilent Bioanalyzer (Agilent Technologies Inc., Santa Clara, California, USA). The amount of RNA was estimated through UV spectrophotometry with a NanoDrop ND-1000 Uv-Vis Spectrophotometer (NanoDrop Technologies, Wilmington, Delaware, USA). Complementary deoxyribonucleic acid (cDNA) was synthesized from total RNA with Super-Script II reverse transcriptase (Invitrogen Corp., Carlsbad, CA, USA) and stored at -80°C .

2.4. Gene Expression Profiling. A TaqMan Endogenous Control Plate was used to check the stability of housekeeping

genes. Gene expression results are expressed as delta Ct (dCt) values and delta-delta Ct (ddCt) values. The dCt values were obtained by subtracting the Ct values of the target genes from Ct values of the most stable housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH; veins), and phosphoglycerate kinase 1 (PGK1; arteries). For ddCt values, further subtractions for irradiated vs unirradiated dCt values were performed. The protocol used has previously been described by Halle et al. [8, 10].

2.5. Immunohistochemistry. Arterial and venous biopsies were sectioned, deparaffinized, and boiled at 750 W in 0.01 M Na-citrate buffer, then heated at 360 W for another 20 minutes to unmask the epitopes. After blocking of endogenous peroxidase (0.5% hydrogen peroxidase in phosphate-buffered saline (PBS)) and unspecific binding (5% normal goat serum in PBS), each for 30 minutes, primary antibodies (PAI-1; Dako Denmark A/S, Glostrup, Denmark) were applied and samples were incubated at 4°C overnight. After washing, the bound peroxidase was visualized by incubation with a DAB substrate kit (diaminobenzidine, SK-4100, Vector Laboratories Inc., CA, USA). Sections were counterstained with Meyer's hematoxylin, dehydrated, and mounted with DPX (Distrene 80, dibutyl phthalate, xylene; BHD Laboratories Supplies, Poole, UK). PAI-1-positive cells were identified and photographed in light microscopy using a Nikon Eclipse Ni microscope (Nikon Corp, Tokyo, Japan) at 200x–600x power. Image processing was undertaken in Adobe Photoshop (Adobe Systems, San Jose, USA).

2.6. Immunofluorescence. After deparaffinization, sections were boiled for 25 minutes in 0.01 M Na-citrate in a 2100 retriever (Electron Microscopy Sciences, Hatfield, PA, USA) to unmask the epitopes. Serum-free protein block (Dako Denmark A/S, Glostrup, Denmark) was used to decrease nonspecific conjugate binding, and primary antibodies (rabbit polyclonal to PAI-1 (ab66705) 1:200, mouse monoclonal to CD45 (ab30470) 1:100, mouse monoclonal to CD68 (ab955) 1:100, and mouse monoclonal to alpha-smooth muscle actin (α -SMA; ab7817) 1:100; Abcam, Cambridge, UK) were incubated at 4°C overnight. 2.5% horse serum in PBS was used as a negative control, and for positive controls, normal human kidney (PAI-1) and tonsil (CD68, CD45) were used.

Secondary antibodies (Alexa Fluor 488 goat anti-mouse, and Alexa Fluor 594 goat anti-rabbit, Thermo Fisher Scientific, MA, USA, 1:1000) were incubated in the darkness for 30 min. DAPI (4',6-diamidino-2-phenylindole; Invitrogen Laboratories Inc., CA, USA) (5 mg/ml, 1:50000 for 20 minutes) was used to visualize the nuclei. After fixation with Dako Fluorescent Mounting Media (Dako Denmark A/S, Glostrup, Denmark), the sections were stored in a dark environment until IF-microscopy and photography were performed with a laser scanning confocal Nikon Eclipse Ni microscope (Nikon Corp, Tokyo, Japan). Image processing was undertaken in Adobe Photoshop (Adobe Systems, San Jose, USA).

FIGURE 1: Serpine1 gene (PAI-1) expression is higher in irradiated arteries (XRT) vs unirradiated arteries (0XRT; ddCt), in relation to PGK1 (dCt), $p = 0.012$.

FIGURE 2: Serpine1 gene (PAI-1) expression is higher in irradiated veins (XRT) vs unirradiated veins (0XRT; ddCt), in relation to GAPDH (dCt), $p < 0.001$.

2.7. Statistics. Wilcoxon's signed-rank test of paired samples was used to test differences between irradiated and unirradiated vessels for RNA levels. Values of $p < 0.05$ were considered significant.

3. Results

3.1. Gene Expression. There was a significant increase of the Serpine1 gene (PAI-1) expression in arteries ($p = 0.012$) and veins ($p < 0.001$) in irradiated compared to unirradiated vessels from the same patient (Figures 1 and 2). The median fold change was 5.05 [0.26–30.0] in arterial samples and 8.32 [1.04–91.3] in the venous samples.

3.2. Immunohistochemistry. Expression of PAI-1 was detected in both irradiated arteries and irradiated veins, mainly in cells located in the adventitia (Figures 3(a)–3(d)). PAI-1-positive cells showed a morphology of mononuclear cells with an oval, or slot-shaped cytoplasm, consistent with the morphology of myofibroblasts and macrophages.

FIGURE 3: Immunohistochemistry showing PAI-1-positive cells (black arrows) in the adventitia of an irradiated artery (a), with a close-up showing the morphology of one such cell (b). Similarly, PAI-1-positive cells were found in the tunica externa of irradiated veins (c), with (d) a shown close-up of one such cell (scale bar = 50 μ m).

No PAI-1 expression was detected in analysed sections from unirradiated arteries or veins (not shown).

3.3. Immunofluorescence. Colocalization of PAI-1 with CD68, CD45, and α -SMA was detected in irradiated arteries. In irradiated veins, colocalization of PAI-1 with CD45 and α -SMA was found. Coexpression of PAI-1 and CD68 was not detected in irradiated veins (Figures 4-8). No PAI-1 positivity was found in unirradiated vessels (not shown).

4. Discussion

We examined irradiated arteries and veins, compared with unirradiated arteries and veins from the same patient, with gene expression analysis of PAI-1, previously known to be associated with an adverse cardiovascular outcome. Further analysis with IHC and IF confirmed the findings on a protein level and showed that the expression was mainly confined to the adventitia. Previous work has shown upregulation of PAI-1, a downstream mediator in the NF- κ B cascade, in irradiated veins after radiotherapy [10]. The increased expression of PAI-1, together with the morphological findings showing its location in the adventitia of both arteries and veins, has never been described before. These results extend previous findings of radiation-induced adventitial inflammation seen in arteries [8].

Several clinical studies have shown that patients previously treated with radiotherapy to the head and neck area or the thoracic region have an increased risk of

cardiovascular events, most commonly occurring several years after exposure [1, 5, 6]. This radiation-induced cardiovascular disease may account for up to a third of non-malignant deaths in groups of cancer survivors, where vascular changes histopathologically resemble those seen in classic atherosclerosis, such as intimal thickening and inflammation [5, 6, 17]. Head and neck cancer patients often have other contributing risk factors for cardiovascular disease (smoking, male gender, and hypertension), and the relative risk for stroke and transient ischemic attack is more than doubled in patients receiving radiotherapy [3]. While Russell et al. found a significant 1.5-fold difference in the intima-media ratio (IMR) in irradiated arteries of the neck compared to unirradiated arteries, the difference was no longer significant when the IMR of the radial artery was analysed as a covariate [5]. In a recent study by our group, we demonstrated that it was the outermost layer of the vessel wall (tunica externa or adventitia) that was chronically inflamed and infiltrated with macrophages in radiation-induced arterial inflammation by means of leukotriene signalling [8].

By primarily affecting the breakdown of fibrin clots through inhibition of tissue plasminogen activator (tPA), a serine protease responsible for the conversion of plasminogen to plasmin, and urokinase-type plasminogen activator, PAI-1 is the main inhibitor of the fibrinolytic system. The majority of circulating PAI-1 is released by activated platelets [18]. A deficiency of PAI-1 leads to moderate bleeding disorders, whereas high levels of PAI-1 can lead to thrombophilia.

FIGURE 4: Double-labelling of PAI-1 (red) and CD68 (green) in an irradiated artery. Arrowheads indicate colocalization of PAI-1 and CD68, suggesting that PAI-1 is expressed in macrophages. Arrows indicate cells with PAI-1 expression but no CD68 expression. Nuclear stain (DAPI) is shown in blue (scale bar = 50 μ m).

Epidemiological studies and SNP-analyses for the PAI-1 locus 7q22.1 (SERPINE1) indicate an elevated risk for the onset of coronary heart disease in patients with high PAI-1 levels, independent of other risk factors [18, 19]. Age, smoking, obesity, insulin, and stress can contribute to increased levels of PAI-1, suggesting a link between impaired fibrinolysis and metabolic and cardiac diseases [20–22]. Conversely, exercise has been shown to correlate inversely to inflammation (measured with C-reactive protein) and plasma fibrinogen, as well as PAI-1 levels [23–25]. The cause and effects of increased PAI-1 levels in cardiovascular disease are thus intriguing from many perspectives. Elevated levels of PAI-1 in head and neck squamous cell carcinoma (HNSCC) have also been connected to a shorter disease-free survival, particularly when there are signs of concomitant perineural invasion [26].

Through inhibiting plasmin-mediated matrix metalloproteinases (MMP) activation, PAI-1 also has a role in the regulation of wound healing by disrupting the normal balance between extracellular matrix (ECM) deposition by myofibroblasts and its clearance by MMPs, thus orienting the process in a profibrotic direction [14, 27]. It has also been suggested that the normal downregulation of myofibroblasts

FIGURE 5: Double-labelling of PAI-1 (red) and CD45 (green) in an irradiated artery. Arrowheads indicate colocalization of PAI-1 and CD45, suggesting expression of PAI-1 in leukocytes. Nuclear stain (DAPI) is shown in blue (scale bar = 50 μ m).

seen in wound healing does not take place in fibrotic states due to impeded control of mediators, e.g., transforming growth factor beta 1 (TGF- β 1) and connective tissue growth factor (CTGF) [28], possibly due to epigenetic changes (such as DNA methylation) that may affect apoptosis [6].

In the acute setting after radiotherapy, activation and dysfunction of the endothelium are believed to create a prothrombotic environment in which adhesion molecules facilitate transmigration of leukocytes to the tissues and an up-regulation of NF- κ B and other inflammatory mediators [6, 9–12, 15]. Previous work in our institution has indirectly indicated that pathological changes in the microvascular bed of free tissue transfers (free flaps) may be the culprit for postoperative complications such as fistula formation and infection [13] and has described chronic inflammatory changes in irradiated arteries and veins [4, 7–11]. The results may be of particular interest for microvascular reconstructions, since previous studies indicate that there may be a role for tPA during the rare event of a reexploration for vascular complications [11]. The outcome for the clinical cohort from which biopsies were taken has been reported elsewhere [13]. However, the value of this study lies in the fact that targeting PAI-1 could be a potential treatment for a growing population of cancer survivors with an increased risk of

FIGURE 6: Double-labelling of PAI-1 (red) and α -SMA (green) in an irradiated artery. Arrowheads indicate colocalization of PAI-1 and α -SMA, suggesting expression of PAI-1 in myofibroblasts. Arrows indicate cells with PAI-1 expression but no α -SMA expression. Nuclear stain (DAPI) is shown in blue (scale bar = 50 μ m).

FIGURE 7: Double-labelling of PAI-1 (red) and CD45 (green) in an irradiated vein. Arrowheads indicate colocalization of PAI-1 and CD45, indicating expression of PAI-1 in leukocytes. Arrows indicate cells with PAI-1 expression but no CD45 expression. Nuclear stain (DAPI) is shown in blue (scale bar = 50 μ m).

localized cardiovascular disease years after radiotherapy. Many targets for pharmaceutical intervention to prevent fibrosis and cardiovascular morbidity after irradiation have been investigated, for example, blocking the renin-angiotensin-aldosterone system through angiotensin-converting enzyme inhibitors and angiotensin receptor blockers or by using statins [29–34]. Tiplaxtinin (PAI-039, a PAI-1-inhibitor) is an interesting pharmacological agent that has been shown to reduce self-renewal and resistance to radiation in tumor-initiating cells in HNSCC [35].

In the chronic setting, inflammation, tissue hypoxia, oxidative stress, and epigenetic changes have been implicated in the pathophysiology of fibrosis [6, 17, 36]. In an irradiated tissue, immune cells secrete inflammatory and profibrotic cytokines such as IL-6, TGF- β 1, CTGF/CCN2, and PAI-1, stimulating the activation of myofibroblasts and endothelial to mesenchymal transition (EndoMT), with resulting increases of deposition of collagen, fibronectin, and α -SMA in the ECM [14, 27, 36–38]. Irradiation also induces the release of bound, latent TGF- β 1 (LTGF- β 1) in the ECM through the actions of reactive oxygen species (ROS), and LTGF- β 1 can analogously be released via proteases such as plasmin, thrombin, and MMPs [6, 14, 15, 28, 39]. Both

TGF- β 1 and CTGF have been shown to have properties that can sustain a fibrotic response through autocrine positive feedback loops affecting the transcription of profibrotic genes through the Smad and Rho pathways [12, 14, 28, 36, 38, 40]. Inhibition of CTGF and PAI-1, as well as ROS-scavengers, has been shown to decrease fibrosis and remodelling in multiple organ systems [6, 12, 36, 38, 41].

CD68+ macrophages have been demonstrated in the adventitia of the arteries, which demonstrated an expanded vasa vasorum and an increased expression of arachidonate 5-lipoxygenase long after treatment [8], indicating a chronic inflammatory response. It has also been suggested that the normal downregulation of myofibroblasts seen in wound healing does not take place in fibrotic states due to the impeded control of mediators, e.g., TGF- β 1 and CTGF [28], possibly due to epigenetic changes (such as DNA methylation) that may affect apoptosis [6].

This study has its limitations, as the total number of included patients is low. However, the comparison between irradiated and unirradiated blood vessels from the same patients excludes most of the possible confounding factors, although differences in the morphology of blood vessels can differ depending on anatomical location [16]. Preferably, all

FIGURE 8: Double-labelling of PAI-1 (red) and α -SMA (green) in an irradiated vein. Arrowheads indicate colocalization of PAI-1 and α -SMA, indicating expression of PAI-1 in myofibroblasts. Arrows indicate cells with PAI-1 expression but no α -SMA expression. Nuclear stain (DAPI) is shown in blue (scale bar = 50 μ m).

arteries and veins would be harvested from the same population, but ethical considerations precluded the use of both arteries and veins in some patients. Some vessels could not be harvested safely in order to obtain a biopsy with sufficient material for both gene expression and immunoassays. However, a majority of the patients (7/12) included contributed to the analyses of both arteries and veins.

5. Conclusions

Patients receiving radiotherapy in the setting of head and neck or breast cancer are prone to develop long-term inflammatory and fibrotic changes in the vasculature that likely contribute to an increased incidence of cardiovascular disease in these groups years after radiation exposure. Classic risk factors for the development of atherosclerosis and individual radiosensitivity as well as the administered dose likely contribute to individual risks. Theoretically, a PAI-1-inhibitor could have a therapeutic potential to reduce cardiovascular morbidity for patients receiving radiotherapy, as well as affecting features of prognostic importance for patients with HNSCC.

Data Availability

Please contact the corresponding author via e-mail for access to relevant data.

Ethical Approval

The study was approved by the Ethical Committee of Stockholm and was performed in agreement with institutional guidelines and the principles of the Declaration of Helsinki.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Acknowledgments

The authors wish to thank Inger Bodin, CCK, Karolinska University Hospital, for the assistance in the preparation and processing of the samples and Associate Professor Liv Eidsmo, CCM, Karolinska Institute, for the supply of research facilities and material. MH is supported by the Cancer Research Funds of Radiumhemmet (grant number 161072), the Swedish Society of Medicine (grant number SLS-248851), and the Stockholm County Council (grant number 20170080).

Supplementary Materials

Individual patient characteristics are listed in Appendix 1. (*Supplementary Materials*)

References

- [1] S. C. Darby, M. Ewertz, P. McGale et al., "Risk of ischemic heart disease in women after radiotherapy for breast cancer," *The New England Journal of Medicine*, vol. 368, no. 11, pp. 987–998, 2013.
- [2] E. Arthurs, T. P. Hanna, K. Zaza, Y. Peng, and S. F. Hall, "Stroke after radiation therapy for head and neck Cancer: what is the risk?," *International Journal of Radiation Oncology, Biology, Physics*, vol. 96, no. 3, pp. 589–596, 2016.
- [3] C. Plummer, R. D. Henderson, J. D. O'Sullivan, and S. J. Read, "Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review," *Stroke*, vol. 42, no. 9, pp. 2410–2418, 2011.
- [4] M. Halle, P. Hall, and P. Tornvall, "Cardiovascular disease associated with radiotherapy: activation of nuclear factor kappa-B," *Journal of Internal Medicine*, vol. 269, no. 5, pp. 469–477, 2011.
- [5] N. S. Russell, S. Hoving, S. Heeneman et al., "Novel insights into pathological changes in muscular arteries of radiotherapy patients," *Radiotherapy and Oncology*, vol. 92, no. 3, pp. 477–483, 2009.
- [6] J. R. Cuomo, G. K. Sharma, P. D. Conger, and N. L. Weintraub, "Novel concepts in radiation-induced cardiovascular disease," *World Journal of Cardiology*, vol. 8, no. 9, pp. 504–519, 2016.
- [7] T. Christersdottir Björklund, S. J. Reilly, C. Gahm et al., "Increased long-term expression of pentraxin 3 in irradiated human arteries and veins compared to internal controls from

- free tissue transfers," *Journal of Translational Medicine*, vol. 11, no. 1, p. 223, 2013.
- [8] M. Halle, T. Christersdottir, and M. Back, "Chronic adventitial inflammation, vasa vasorum expansion, and 5-lipoxygenase up-regulation in irradiated arteries from cancer survivors," *The FASEB Journal*, vol. 30, no. 11, pp. 3845–3852, 2016.
 - [9] M. Halle, A. Gabrielsen, G. Paulsson-Berne et al., "Sustained inflammation due to nuclear factor-kappa B activation in irradiated human arteries," *Journal of the American College of Cardiology*, vol. 55, no. 12, pp. 1227–1236, 2010.
 - [10] M. Halle, M. Ekström, F. Farnebo, and P. Tornvall, "Endothelial activation with prothrombotic response in irradiated microvascular recipient veins," *Journal of Plastic, Reconstructive & Aesthetic Surgery*, vol. 63, no. 11, pp. 1910–1916, 2010.
 - [11] J. Tall, T. C. Björklund, A. C. D. Skogh, C. Arnander, and M. Halle, "Vascular complications after radiotherapy in head and neck free flap reconstruction: clinical outcome related to vascular biology," *Annals of Plastic Surgery*, vol. 75, no. 3, pp. 309–315, 2015.
 - [12] A. A. Khan, J. T. Paget, M. McLaughlin et al., "Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues," *Science Translational Medicine*, vol. 10, no. 425, p. eaar2041, 2018.
 - [13] M. Halle, B. O. Eriksson, A. C. Docherty Skogh, P. Sommar, L. Hammarstedt, and C. Gahm, "Improved head and neck free flap outcome-effects of a treatment protocol adjustment from pre- to postoperative radiotherapy," *Plastic and Reconstructive Surgery - Global Open*, vol. 5, no. 3, article e1253, 2017.
 - [14] J. Yarnold and M. C. Vozenin Brotons, "Pathogenetic mechanisms in radiation fibrosis," *Radiotherapy and Oncology*, vol. 97, no. 1, pp. 149–161, 2010.
 - [15] R. L. Stansborough, N. al-dasooqi, E. H. Bateman, D. M. K. Keefe, and R. J. Gibson, "Radiotherapy-induced gut toxicity: involvement of matrix metalloproteinases and the intestinal microvasculature," *International Journal of Radiation Biology*, vol. 92, no. 5, pp. 241–248, 2016.
 - [16] H. B. Stone, C. N. Coleman, M. S. Anscher, and W. H. McBride, "Effects of radiation on normal tissue: consequences and mechanisms," *The Lancet Oncology*, vol. 4, no. 9, pp. 529–536, 2003.
 - [17] N. L. Weintraub, W. K. Jones, and D. Manka, "Understanding radiation-induced vascular disease," *Journal of the American College of Cardiology*, vol. 55, no. 12, pp. 1237–1239, 2010.
 - [18] C. Whyte, J. Mitchell, and N. Mutch, "Platelet-mediated modulation of fibrinolysis," *Seminars in Thrombosis and Hemostasis*, vol. 43, no. 2, pp. 115–128, 2017.
 - [19] C. Song, S. Burgess, J. D. Eicher, C. J. O'Donnell, and A. D. Johnson, "Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease," *Journal of the American Heart Association*, vol. 6, no. 6, p. e004918, 2017.
 - [20] M. Cesari, M. Pahor, and R. A. Incalzi, "Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions," *Cardiovascular Therapeutics*, vol. 28, no. 5, pp. e72–e91, 2010.
 - [21] M. M. Baluta and M. M. Vintila, "PAI-1 inhibition-another therapeutic option for cardiovascular protection," *Maedica*, vol. 10, no. 2, pp. 147–152, 2015.
 - [22] A. Nordenhem, K. Leander, J. Hallqvist, U. de Faire, M. Sten-Linder, and B. Wiman, "The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project," *Thrombosis Research*, vol. 116, no. 3, pp. 223–232, 2005.
 - [23] F. S. Lira, J. C. Rosa, A. E. Lima-Silva et al., "Sedentary subjects have higher PAI-1 and lipoproteins levels than highly trained athletes," *Diabetology and Metabolic Syndrome*, vol. 2, no. 1, p. 7, 2010.
 - [24] P. Kokkinos and J. Myers, "Exercise and physical activity: clinical outcomes and applications," *Circulation*, vol. 122, no. 16, pp. 1637–1648, 2010.
 - [25] D. S. Hittel, W. E. Kraus, and E. P. Hoffman, "Skeletal muscle dictates the fibrinolytic state after exercise training in overweight men with characteristics of metabolic syndrome," *The Journal of Physiology*, vol. 548, no. 2, pp. 401–410, 2003.
 - [26] L. Speleman, J. D. F. Kerrebijn, M. P. Look, C. A. Meeuwis, J. A. Foekens, and E. M. J. J. Berns, "Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma," *Head & Neck*, vol. 29, no. 4, pp. 341–350, 2007.
 - [27] P. Flevaris and D. Vaughan, "The role of plasminogen activator inhibitor type-1 in fibrosis," *Seminars in Thrombosis and Hemostasis*, vol. 43, no. 2, pp. 169–177, 2017.
 - [28] M. Martin, J. L. Lefaix, and S. Delanian, "TGF- β 1 and radiation fibrosis: a master switch and a specific therapeutic target?," *International Journal of Radiation Oncology, Biology, Physics*, vol. 47, no. 2, pp. 277–290, 2000.
 - [29] G. Fritz, C. Henninger, and J. Huelsenbeck, "Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents," *British Medical Bulletin*, vol. 97, no. 1, pp. 17–26, 2011.
 - [30] M. H. Gaugler, V. Vereycken-Holler, C. Squiban, M. Vandamme, M. C. Vozenin-Brotons, and M. Benderitter, "Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses," *Radiation Research*, vol. 163, no. 5, pp. 479–487, 2005.
 - [31] V. Holler, V. Buard, M. H. Gaugler et al., "Pravastatin limits radiation-induced vascular dysfunction in the skin," *The Journal of Investigative Dermatology*, vol. 129, no. 5, pp. 1280–1291, 2009.
 - [32] S. J. van der Veen, G. Ghobadi, R. A. de Boer et al., "ACE inhibition attenuates radiation-induced cardiopulmonary damage," *Radiotherapy and Oncology*, vol. 114, no. 1, pp. 96–103, 2015.
 - [33] V. Mehta, "Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention," *International Journal of Radiation Oncology, Biology, Physics*, vol. 63, no. 1, pp. 5–24, 2005.
 - [34] S. L. Heck, G. Gulati, A. Hansen Ree et al., "Rationale and design of the prevention of cardiac dysfunction during an adjuvant breast cancer therapy (PRADA) trial," *Cardiology*, vol. 123, no. 4, pp. 240–247, 2012.
 - [35] Y.-C. Lee, C.-C. Yu, C. Lan et al., "Plasminogen activator inhibitor-1 as regulator of tumor-initiating cell properties in head and neck cancers," *Head & Neck*, vol. 38, Supplement 1, pp. E895–E904, 2016.
 - [36] E. L. Travis, G. Rachakonda, X. Zhou et al., "NRF2 deficiency reduces life span of mice administered thoracic irradiation," *Free Radical Biology & Medicine*, vol. 51, no. 6, pp. 1175–1183, 2011.
 - [37] V. Monceau, L. Meziani, C. Strup-Perrot et al., "Enhanced sensitivity to low dose irradiation of ApoE $^{-/-}$ mice mediated by early pro-inflammatory profile and delayed activation of

- the TGF β 1 cascade involved in fibrogenesis,” *PLoS One*, vol. 8, no. 2, article e57052, 2013.
- [38] K. E. Lipson, C. Wong, Y. Teng, and S. Spong, “CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis,” *Fibrogenesis & Tissue Repair*, vol. 5, Supplement 1, p. S24, 2012.
- [39] J. J. C. M. Kruse, B. G. J. Froot, J. A. M. te Poele, N. S. Russell, and F. A. Stewart, “Radiation-induced activation of TGF-beta signaling pathways in relation to vascular damage in mouse kidneys,” *Radiation Research*, vol. 171, no. 2, pp. 188–197, 2009.
- [40] V. Haydont, B. L. Riser, J. Aigueperse, and M. C. Vozenin-Brotons, “Specific signals involved in the long-term maintenance of radiation-induced fibrogenic differentiation: a role for CCN2 and low concentration of TGF- β 1,” *American Journal of Physiology. Cell Physiology*, vol. 294, no. 6, pp. C1332–C1341, 2008.
- [41] S. Bickelhaupt, C. Erbel, C. Timke et al., “Effects of CTGF blockade on attenuation and reversal of radiation-induced pulmonary fibrosis,” *Journal of the National Cancer Institute*, vol. 109, no. 8, 2017.